Keryx Biopharmaceuticals Inc. Sets New 1-Year High at $11.79 (KERX)
Keryx Biopharmaceuticals (NASDAQ:KERX) set a new 52-week high during trading on Thursday, AmericanBankingNews.com reports. The stock traded as high as $11.79 and last traded at $11.55, with a volume of 8,320,815 shares. The stock had previously closed at $10.49.
A number of analysts have recently weighed in on KERX shares. Analysts at Ladenburg Thalmann raised their price target on shares of Keryx Biopharmaceuticals from $15.00 to $19.00 in a research note to investors on Thursday. They now have a “buy” rating on the stock. Separately, analysts at Brean Capital set a $20.00 price target on shares of Keryx Biopharmaceuticals in a research note to investors on Wednesday. They now have a “positive” rating on the stock. Finally, analysts at Roth Capital raised their price target on shares of Keryx Biopharmaceuticals to $24.00 in a research note to investors on Wednesday. Nine investment analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and an average price target of $13.80.
Keryx Biopharmaceuticals has a one year low of $2.23 and a one year high of $10.92. The stock’s 50-day moving average is $9.52 and its 200-day moving average is $8.47. The company’s market cap is $942.5 million.
Keryx Biopharmaceuticals (NASDAQ:KERX) last released its earnings data on Thursday, August 1st. The company reported ($0.14) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.10) by $0.04. During the same quarter last year, the company posted ($0.02) earnings per share. On average, analysts predict that Keryx Biopharmaceuticals will post $-0.42 earnings per share for the current fiscal year.
Keryx Biopharmaceuticals, Inc (NASDAQ:KERX) is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and renal disease.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.